Advanced in Intraductal Papilloma

Dr. Christopher M. Gallagher

Hematology Oncology | Hematology | Oncology
Tidalhealth Specialty Care LLC
100 E Carroll St, 
Salisbury, MD 
Advanced in Intraductal Papilloma
Tidalhealth Specialty Care LLC
100 E Carroll St, 
Salisbury, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Gallagher is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Gallagher is rated as an Advanced provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Hospital Affiliations
Tidalhealth Peninsula Regional, Inc
Tidalhealth Nanticoke, Inc.
Centra Health - Lynchburg Gen Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

TIDALHEALTH SPECIALTY CARE LLC
100 E Carroll St, Salisbury, MD 21801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Capecitabine
Study Phase: Phase 2
evaLuation of Variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA Study
evaLuation of Variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA Study
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2023
Intervention Type: Drug
Study Drug: SM-88
Study Phase: Phase 2
Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: September 28, 2021
Intervention Type: Drug
Study Drug: Palbociclib + Letrozole or Fulvestrant
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials

29 Total Publications

Feasibility and Acceptability of a Positive Psychological Intervention for Patients With Metastatic Breast Cancer: Pre-Post Pilot Study.
Feasibility and Acceptability of a Positive Psychological Intervention for Patients With Metastatic Breast Cancer: Pre-Post Pilot Study.
Journal: JMIR formative research
Published: May 16, 2025
Similar Doctors
Distinguished in Intraductal Papilloma
Dr. Gurdeep S. Chhabra
Hematology Oncology | Hematology | Oncology
Distinguished in Intraductal Papilloma
Dr. Gurdeep S. Chhabra
Hematology Oncology | Hematology | Oncology

Medstar Medical Group - Southern Maryland LLC

22590 Shady Ct, 
California, MD 
 (48.1 miles away)
301-373-7900
Languages Spoken:
English, French, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Gurdeep Chhabra is a Hematologist Oncology specialist and a Hematologist in California, Maryland. Dr. Chhabra is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Small Cell Lung Cancer (SCLC). Dr. Chhabra is currently accepting new patients.

Distinguished in Intraductal Papilloma
Dr. Kathrina L. Chua
Hematology Oncology | Oncology
Distinguished in Intraductal Papilloma
Dr. Kathrina L. Chua
Hematology Oncology | Oncology

Bayhealth Medical Center, Inc

640 S State St, Bayhlth Kent Campus, 
Dover, DE 
 (54.7 miles away)
302-744-7000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathrina Chua is a Hematologist Oncology specialist and an Oncologist in Dover, Delaware. Dr. Chua is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. Her top areas of expertise are Idiopathic Neutropenia, Paget Disease of the Breast, Familial Colorectal Cancer, and Intraductal Papilloma. Dr. Chua is currently accepting new patients.

Advanced in Intraductal Papilloma
Dr. Nisarg R. Desai
Hematology Oncology | Hematology | Oncology
Advanced in Intraductal Papilloma
Dr. Nisarg R. Desai
Hematology Oncology | Hematology | Oncology

Beebe Medical Center Inc

424 Savannah Rd, 
Lewes, DE 
 (37.4 miles away)
302-645-3300
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Nisarg Desai is a Hematologist Oncology specialist and a Hematologist in Lewes, Delaware. Dr. Desai is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Hemochromatosis, Essential Thrombocythemia, Thrombocytopenia, and Lymphomatoid Papulosis. Dr. Desai is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gallagher's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile